Literature DB >> 33659347

Tyramide Signal-Amplified Immunofluorescence of MYCN and MYC in Human Tissue Specimens and Cell Line Cultures.

Johanna M Schafer1, Jennifer A Pietenpol1,2.   

Abstract

MYC family members, MYC, MYCN, and MYCL, are oncogenic transcription factors that regulate the expression of genes involved in normal development, cell growth, proliferation, metabolism, and survival. While MYC is amplified and/or overexpressed across a variety of tissue types, MYCN is often overexpressed in tumors of the nervous system (neuroblastoma and medulloblastoma) or with neuroendocrine features (neuroendocrine prostate cancer). Given recent reports that MYCN expression is also deregulated in a variety of non-neuronal tissue types, we investigated whether MYCN was also deregulated in triple-negative breast cancer (TNBC). In contrast to previous individual immuno-fluorescence (IF) stains against higher expressing MYC family isoform protein, we developed an IF stain to simultaneously detect both MYCN- and MYC-expressing cells within the same tumor cell population. Our methodology allows for the detection of low level MYCN and MYC expression and can be multiplexed with additional protein probes. Herein, using tyramide signal amplification (TSA), we present two protocols for the IF detection of MYCN and MYC on formalin-fixed paraffin embedded (FFPE) tumor sections and in cell lines fixed in situ after growth as adherent cultures on chambered microscope slides.
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Cancer biology; Chamber slides; Immunofluorescence; MYC; MYCN; Tyramide signal amplification

Year:  2020        PMID: 33659347      PMCID: PMC7842564          DOI: 10.21769/BioProtoc.3677

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  8 in total

1.  N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation.

Authors:  B A Malynn; I M de Alboran; R C O'Hagan; R Bronson; L Davidson; R A DePinho; F W Alt
Journal:  Genes Dev       Date:  2000-06-01       Impact factor: 11.361

Review 2.  Control of vertebrate development by MYC.

Authors:  Peter J Hurlin
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

3.  Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis.

Authors:  K Funa; L Steinholtz; E Nou; J Bergh
Journal:  Am J Clin Pathol       Date:  1987-08       Impact factor: 2.493

4.  An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.

Authors:  Maria Giuseppina Baratta; Anna C Schinzel; Yaara Zwang; Pratiti Bandopadhayay; Christian Bowman-Colin; Jennifer Kutt; Jennifer Curtis; Huiying Piao; Laura C Wong; Andrew L Kung; Rameen Beroukhim; James E Bradner; Ronny Drapkin; William C Hahn; Joyce F Liu; David M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 5.  The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.

Authors:  Himisha Beltran
Journal:  Mol Cancer Res       Date:  2014-03-03       Impact factor: 5.852

6.  Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice.

Authors:  Hiroyuki Kawagoe; Ayten Kandilci; Tanya A Kranenburg; Gerard C Grosveld
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

7.  Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells.

Authors:  Devon A Lawson; Nirav R Bhakta; Kai Kessenbrock; Karin D Prummel; Ying Yu; Ken Takai; Alicia Zhou; Henok Eyob; Sanjeev Balakrishnan; Chih-Yang Wang; Paul Yaswen; Andrei Goga; Zena Werb
Journal:  Nature       Date:  2015-09-23       Impact factor: 49.962

8.  Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors.

Authors:  Johanna M Schafer; Brian D Lehmann; Paula I Gonzalez-Ericsson; Clayton B Marshall; J Scott Beeler; Lindsay N Redman; Hailing Jin; Violeta Sanchez; Matthew C Stubbs; Peggy Scherle; Kimberly N Johnson; Quanhu Sheng; Joseph T Roland; Joshua A Bauer; Yu Shyr; Bapsi Chakravarthy; Bret C Mobley; Scott W Hiebert; Justin M Balko; Melinda E Sanders; Phillip C C Liu; Jennifer A Pietenpol
Journal:  Sci Transl Med       Date:  2020-03-11       Impact factor: 17.956

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.